Free Trial
NASDAQ:LUCD

Lucid Diagnostics (LUCD) Stock Price, News & Analysis

Lucid Diagnostics logo
$1.06 +0.02 (+1.92%)
Closing price 04:00 PM Eastern
Extended Trading
$1.06 0.00 (0.00%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lucid Diagnostics Stock (NASDAQ:LUCD)

Key Stats

Today's Range
$1.03
$1.11
50-Day Range
$1.04
$1.59
52-Week Range
$0.72
$1.80
Volume
958,298 shs
Average Volume
672,165 shs
Market Capitalization
$114.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.55
Consensus Rating
Buy

Company Overview

Lucid Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

LUCD MarketRank™: 

Lucid Diagnostics scored higher than 43% of companies evaluated by MarketBeat, and ranked 618th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lucid Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lucid Diagnostics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Lucid Diagnostics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.84) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lucid Diagnostics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lucid Diagnostics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Lucid Diagnostics' valuation and earnings.
  • Percentage of Shares Shorted

    4.12% of the float of Lucid Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lucid Diagnostics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lucid Diagnostics has recently increased by 53.70%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lucid Diagnostics does not currently pay a dividend.

  • Dividend Growth

    Lucid Diagnostics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.12% of the float of Lucid Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lucid Diagnostics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lucid Diagnostics has recently increased by 53.70%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 6 people have searched for LUCD on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lucid Diagnostics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.80% of the stock of Lucid Diagnostics is held by insiders.

  • Percentage Held by Institutions

    74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lucid Diagnostics' insider trading history.
Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

LUCD Stock News Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
See More Headlines

LUCD Stock Analysis - Frequently Asked Questions

Lucid Diagnostics' stock was trading at $0.8187 at the beginning of the year. Since then, LUCD stock has increased by 29.5% and is now trading at $1.06.

Lucid Diagnostics Inc. (NASDAQ:LUCD) posted its earnings results on Tuesday, March, 26th. The company reported ($0.26) earnings per share for the quarter. The company had revenue of $1.04 million for the quarter.
Read the conference call transcript
.

Lucid Diagnostics (LUCD) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share.

Lucid Diagnostics' top institutional investors include Parallel Advisors LLC (0.04%).
View institutional ownership trends
.

Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lucid Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Netflix (NFLX), Clean Energy Fuels (CLNE) and Baidu (BIDU).

Company Calendar

Last Earnings
3/26/2024
Today
7/08/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LUCD
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.55
High Stock Price Target
$7.75
Low Stock Price Target
$2.00
Potential Upside/Downside
+233.3%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.53 million
Net Margins
-1,699.86%
Pretax Margin
-1,481.55%

Debt

Sales & Book Value

Annual Sales
$4.35 million
Price / Cash Flow
N/A
Book Value
($0.78) per share
Price / Book
-1.37

Miscellaneous

Free Float
100,832,000
Market Cap
$115.22 million
Optionable
No Data
Beta
1.23
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:LUCD) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners